{
  "docId": "019de077-8566-7247-8a65-bb40d287c138",
  "docSlug": "3a5ef691e659aba2296672e3bbfa035c",
  "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 36 slides",
  "authorId": "an2-therapeutics",
  "authorName": "AN2 Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2025-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 36,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide presents post-hoc analysis data for a clinical trial, highlighting a statistically significant improvement in the treatment group.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-8566-7247-8a65-bb40d287c138/13",
  "deckHref": "/decks/019de077-8566-7247-8a65-bb40d287c138",
  "deckJsonHref": "/decks/019de077-8566-7247-8a65-bb40d287c138.json",
  "deckAnchorHref": "/decks/019de077-8566-7247-8a65-bb40d287c138#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.33,
        "x": 0.64,
        "y": 0.23
      },
      "kind": "callout",
      "text": "Key insights: Score reduction indicates clinical improvement; Post-hoc analysis; Nominal statistical significance*; Analysis suggests validated MACrO2 continuous measure in TR-MAC, subject to FDA alignment; Reinforces evidence of EBO’s potential clinical effect.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "650fbb5e-2641-4641-b754-9c11233992fa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.55,
        "x": 0.03,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Line chart showing MACrO2 scores over time for Placebo+OBR and EBO+OBR groups.",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "462352de-8667-4800-a448-5b4c3ebf49a6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.33,
        "x": 0.64,
        "y": 0.74
      },
      "kind": "source-note",
      "text": "*Statistical significance shown; considered “nominal” because continuous MACrO2 score was not a prespecified endpoint in Phase 2 and was conducted as a post-hoc analysis",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "91262feb-12bd-4717-b25a-a36ebf7d938f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.94,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "MACrO2 Analysis as Continuous Score Reinforces Outcomes Observed in QOL-B Respiratory Domain",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4c71a37f-cd8c-4fa0-ae43-464461e72230",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.3,
        "x": 0.03,
        "y": 0.21
      },
      "kind": "title",
      "text": "MACrO2 clinical response (least squares mean)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f07107fd-54b9-49ba-9d68-1be810e317e7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Waterfall chart",
      "slug": "waterfall-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "c58d1a5c-754e-4f87-a98b-73ccebc4b16e",
      "evidence": "Line chart showing MACrO2 scores over time for Placebo+OBR and EBO+OBR groups.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 9,
      "beatId": "97a1ede8-85ba-45c5-94c2-981cd0dfd720",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The document presents clinical trial results and other traction metrics for AN2 Therapeutics' pipeline candidates.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}